Immunotherapy for cardiovascular disease

Elisa Martini, Giuliano Giuseppe Stirparo, Marinos Kallikourdis

Research output: Contribution to journalReview article

3 Citations (Scopus)

Abstract

Heart failure (HF), the final stage of pathological cardiac hypertrophy, is a major cause of hospitalization and mortality. The role of inflammation in the pathogenesis of HF has been extensively studied, with great emphasis on proinflammatory cytokines. Yet, clinical trials targeting these cytokines failed to become a credible therapeutic strategy for HF. More recent studies are increasingly highlighting an active role for T cells in the progression of HF pathology. As a result, a number of novel immunotherapy strategies are emerging for the treatment of HF and other cardiovascular diseases, via the targeting of adaptive immunity. Here we provide an overview of the background, details, and expected outcomes of these attempts.

Original languageEnglish
JournalJournal of Leukocyte Biology
DOIs
Publication statusE-pub ahead of print - Dec 19 2017

Fingerprint

Immunotherapy
Cardiovascular Diseases
Heart Failure
Cytokines
Cardiomegaly
Adaptive Immunity
Treatment Failure
Hospitalization
Clinical Trials
Pathology
Inflammation
T-Lymphocytes
Mortality
Therapeutics

Keywords

  • Journal Article
  • Review

Cite this

Immunotherapy for cardiovascular disease. / Martini, Elisa; Stirparo, Giuliano Giuseppe; Kallikourdis, Marinos.

In: Journal of Leukocyte Biology, 19.12.2017.

Research output: Contribution to journalReview article

@article{4ed3b39f69d743e4a9d68ae8233f9946,
title = "Immunotherapy for cardiovascular disease",
abstract = "Heart failure (HF), the final stage of pathological cardiac hypertrophy, is a major cause of hospitalization and mortality. The role of inflammation in the pathogenesis of HF has been extensively studied, with great emphasis on proinflammatory cytokines. Yet, clinical trials targeting these cytokines failed to become a credible therapeutic strategy for HF. More recent studies are increasingly highlighting an active role for T cells in the progression of HF pathology. As a result, a number of novel immunotherapy strategies are emerging for the treatment of HF and other cardiovascular diseases, via the targeting of adaptive immunity. Here we provide an overview of the background, details, and expected outcomes of these attempts.",
keywords = "Journal Article, Review",
author = "Elisa Martini and Stirparo, {Giuliano Giuseppe} and Marinos Kallikourdis",
note = "{\circledC}2017 Society for Leukocyte Biology.",
year = "2017",
month = "12",
day = "19",
doi = "10.1002/JLB.5MR0717-306R",
language = "English",
journal = "Journal of Leukocyte Biology",
issn = "0741-5400",
publisher = "FASEB",

}

TY - JOUR

T1 - Immunotherapy for cardiovascular disease

AU - Martini, Elisa

AU - Stirparo, Giuliano Giuseppe

AU - Kallikourdis, Marinos

N1 - ©2017 Society for Leukocyte Biology.

PY - 2017/12/19

Y1 - 2017/12/19

N2 - Heart failure (HF), the final stage of pathological cardiac hypertrophy, is a major cause of hospitalization and mortality. The role of inflammation in the pathogenesis of HF has been extensively studied, with great emphasis on proinflammatory cytokines. Yet, clinical trials targeting these cytokines failed to become a credible therapeutic strategy for HF. More recent studies are increasingly highlighting an active role for T cells in the progression of HF pathology. As a result, a number of novel immunotherapy strategies are emerging for the treatment of HF and other cardiovascular diseases, via the targeting of adaptive immunity. Here we provide an overview of the background, details, and expected outcomes of these attempts.

AB - Heart failure (HF), the final stage of pathological cardiac hypertrophy, is a major cause of hospitalization and mortality. The role of inflammation in the pathogenesis of HF has been extensively studied, with great emphasis on proinflammatory cytokines. Yet, clinical trials targeting these cytokines failed to become a credible therapeutic strategy for HF. More recent studies are increasingly highlighting an active role for T cells in the progression of HF pathology. As a result, a number of novel immunotherapy strategies are emerging for the treatment of HF and other cardiovascular diseases, via the targeting of adaptive immunity. Here we provide an overview of the background, details, and expected outcomes of these attempts.

KW - Journal Article

KW - Review

U2 - 10.1002/JLB.5MR0717-306R

DO - 10.1002/JLB.5MR0717-306R

M3 - Review article

C2 - 29345361

JO - Journal of Leukocyte Biology

JF - Journal of Leukocyte Biology

SN - 0741-5400

ER -